Growth Metrics

Biogen (BIIB) EPS (Basic) (2016 - 2026)

Biogen has reported EPS (Basic) over the past 18 years, most recently at $2.17 for Q1 2026.

  • For Q1 2026, EPS (Basic) rose 31.52% year-over-year to $2.17; the TTM value through Mar 2026 reached $9.35, down 7.97%, while the annual FY2025 figure was $8.83, 21.23% down from the prior year.
  • EPS (Basic) for Q1 2026 was $2.17 at Biogen, up from -$0.33 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $7.86 in Q3 2022 and troughed at -$0.47 in Q3 2023.
  • A 5-year average of $3.02 and a median of $2.69 in 2023 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): skyrocketed 668.09% in 2024 and later crashed 118.03% in 2025.
  • Year by year, EPS (Basic) stood at $3.84 in 2022, then crashed by 55.21% to $1.72 in 2023, then grew by 6.4% to $1.83 in 2024, then crashed by 118.03% to -$0.33 in 2025, then soared by 757.58% to $2.17 in 2026.
  • Business Quant data shows EPS (Basic) for BIIB at $2.17 in Q1 2026, -$0.33 in Q4 2025, and $3.18 in Q3 2025.